Free Trial

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

+0.31 (+0.63%)
(As of 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
355,876 shs
Average Volume
598,745 shs
Market Capitalization
$3.02 billion
P/E Ratio
Dividend Yield
Price Target

Rhythm Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
10.9% Upside
$54.33 Price Target
Short Interest
15.15% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.10mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$973,772 Sold Last Quarter
Proj. Earnings Growth
From ($4.45) to ($2.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.82 out of 5 stars

Medical Sector

376th out of 896 stocks

Pharmaceutical Preparations Industry

178th out of 425 stocks

RYTM stock logo

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM Stock Price History

RYTM Stock News Headlines

AI’s Biggest Problem
Nvidia's been quietly pivoting to another, potentially lucrative business. Nvidia's own CEO, Jensen Huang, believes Big Tech is going to spend over $1 trillion on this part of the business over the next four years.
AI’s Biggest Problem
Nvidia's been quietly pivoting to another, potentially lucrative business. Nvidia's own CEO, Jensen Huang, believes Big Tech is going to spend over $1 trillion on this part of the business over the next four years.
Rhythm Pharmaceuticals, Inc. (RYTM)
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$91.93 million
Book Value
$2.87 per share


Free Float
Market Cap
$2.99 billion
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

RYTM Stock Analysis - Frequently Asked Questions

How have RYTM shares performed this year?

Rhythm Pharmaceuticals' stock was trading at $45.97 at the beginning of the year. Since then, RYTM stock has increased by 6.5% and is now trading at $48.98.
View the best growth stocks for 2024 here

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($2.35) earnings per share for the quarter, missing analysts' consensus estimates of ($2.34) by $0.01. The firm's revenue for the quarter was up 126.1% compared to the same quarter last year.

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.38%), Wedge Capital Management L L P NC (0.10%), Harbor Capital Advisors Inc. (0.06%) and SG Americas Securities LLC (0.06%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, William T Roberts, Jennifer Chien, Jennifer Kayden Lee, Christopher Paul German and Joseph Shulman.
View institutional ownership trends

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN) and Kadmon (KDMN).

This page (NASDAQ:RYTM) was last updated on 7/19/2024 by Staff

From Our Partners